Burden of illness in Japanese patients with paroxysmal nocturnal hemoglobinuria receiving C5 inhibitors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Burden of illness in Japanese patients with paroxysmal nocturnal hemoglobinuria receiving C5 inhibitors ; volume:119 ; number:3 ; day:19 ; month:1 ; year:2024 ; pages:255-264 ; date:3.2024
International journal of hematology ; 119, Heft 3 (19.1.2024), 255-264, 3.2024
- Creator
-
Obara, Naoshi
Usuki, Kensuke
Hayashi, Takeshi
Fujii, Masato
Ikezoe, Takayuki
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12185-023-03698-5
- URN
-
urn:nbn:de:101:1-2405102120215.857691510772
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Obara, Naoshi
- Usuki, Kensuke
- Hayashi, Takeshi
- Fujii, Masato
- Ikezoe, Takayuki
- SpringerLink (Online service)
Other Objects (12)
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective
The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life
Paroxysmal nocturnal hemoglobinuria: Where we stand
The complement model disease paroxysmal nocturnal hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment
Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH)
Correction to: Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
Paroxysmal nocturnal hemoglobinuria and related disorders : molecular aspects of pathogenesis
Paroxysmal nocturnal hemoglobinuria in systemic lupus erythematosus: a case report
Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients
Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective
The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life
Paroxysmal nocturnal hemoglobinuria: Where we stand
The complement model disease paroxysmal nocturnal hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment
Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH)
Correction to: Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
Paroxysmal nocturnal hemoglobinuria and related disorders : molecular aspects of pathogenesis
Paroxysmal nocturnal hemoglobinuria in systemic lupus erythematosus: a case report
Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients
Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective
The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life
Paroxysmal nocturnal hemoglobinuria: Where we stand
The complement model disease paroxysmal nocturnal hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment
Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH)
Correction to: Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
Paroxysmal nocturnal hemoglobinuria and related disorders : molecular aspects of pathogenesis
Paroxysmal nocturnal hemoglobinuria in systemic lupus erythematosus: a case report
Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients